Project Preferences and Evaluation Criteria


The IPDC Fund is seeking to invest in technologies with the potential to achieve transformative rather than incremental advances in cancer prevention, detection, diagnosis and treatment. The list below describes the type of projects in which we prefer to invest.

  • Therapeutics:
    • New chemical entities or biologics addressing novel targets and/or new mechanisms of action;
  • Medical technology:
    • Major advances in devices, imaging, therapeutic energy delivery, software;
  • New technology platforms:
    • Examples include drug delivery, personalized medicine.

Applications to the IPDC Fund are evaluated by the OICR Commercialization team and external expert reviewers selected from academia and industry for subject-specific expertise. Applications are evaluated according to the following criteria (in no particular order):

  • Significant business opportunity – differentiated and competitive technology for a defined market segment;
  • Cutting edge technology that is transformative not incremental;
  • Regulatory strategy – clarity of the path, territories, time and money required;
  • Strong IP position – breadth, defensibility, blocking ability, freedom to operate;
  • Ability of IPDC funding to advance the technology to a value inflection point;
  • Addressing an unmet need for cancer patients and/or cancer clinicians;
  • Economic benefit to Ontario;
  • Suitability of the team for executing the work plan.